Last updated: June 7, 2026
ecutive summary: No complete, verifiable drug-identity inputs are provided for “BRYNOVIN” (active ingredient, dosage form/strength, country/brand owner, or FDA/NDC label). Without that, it is not possible to produce an accurate supplier map (API/manufacturer, contract manufacturing, packaging, or distributor network) suitable for patent, regulatory, or commercial use.
Suppliers for BRYNOVIN (drug brand)
Answer: Not available from the provided input. A supplier list requires the underlying drug identity (INN, dosage form/strength, and jurisdiction) to link to label, NDC/GTIN, Orange Book/Drug List entries, and cGMP manufacturing sites.
What counts as a “supplier” for BRYNOVIN?
- API supplier (active pharmaceutical ingredient manufacturer, including DMF holders if applicable)
- Finished dosage manufacturer (tablet/capsule/sterile fill-finish site)
- Packager/labeler (secondary packaging and labeling)
- Market distributor (wholesaler and channel partners tied to the labeled NDC)
What company manufactures BRYNOVIN?
Answer: Not available from the provided input.
Which manufacturing sites typically appear on the BRYNOVIN label?
- The labeled manufacturer and packager/labeler listed on the product label and NDC record.
- For sterile products, the fill-finish site is often separate from API production.
Who supplies the API for BRYNOVIN?
Answer: Not available from the provided input.
How to identify the API manufacturer in practice
- Link brand to its INN and strength/dosage form, then use:
- FDA Drugs@FDA label (for U.S.)
- Orange Book (if applicable)
- DMF references when disclosed
- Third-party cGMP databases only after product identity is confirmed
What are BRYNOVIN’s contract manufacturing partners (CMOs)?
Answer: Not available from the provided input.
Common CMO roles
- Solid oral CMOs (blending, granulation, tableting, coating, blistering/bottling)
- Sterile CMOs (if applicable): aseptic fill-finish, lyophilization, sterilization
What is the Orange Book status of BRYNOVIN (and does it affect suppliers)?
Answer: Not available from the provided input.
How Orange Book data drives supplier mapping
- Orange Book listings can connect to:
- Approved application holder
- Patent-protected components (which can narrow possible API/finish suppliers)
- Authorized generic or license agreements
What generic or biosimilar suppliers compete with BRYNOVIN?
Answer: Not available from the provided input.
Why supplier mapping depends on the active ingredient
- Competitive suppliers track the same INN across brands and strengths.
Where are BRYNOVIN shipments sourced from (distribution and logistics)?
Answer: Not available from the provided input.
Typical distribution data sources
- Label and package insert “distributed by” entities
- NDC wholesaler channel coverage
- Regional importers tied to country-specific authorization
Key Takeaways
- A supplier list for BRYNOVIN cannot be built from the provided input because “BRYNOVIN” alone does not uniquely identify the drug.
- Supplier identification requires product identity (active ingredient and dosage form/strength) tied to authoritative label or regulatory records.
- With that identity, a complete supplier map can be produced across API, finished dosage manufacturing, packaging/labeling, and distribution.
FAQs
- How do I find the API supplier behind a drug brand name?
- What label fields identify the finished-dose manufacturer and packager?
- How does an Orange Book entry change the supplier landscape?
- What’s the fastest way to map suppliers by NDC instead of brand name?
- How do contract manufacturing arrangements show up in regulatory documents?
References
- FDA. Drugs@FDA (Prescribing Information and Label).
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
